Short answer
MANNKIND CORP (MNKD) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $90M (up 15.1% year over year) with net income of −$17M.
Q1 2026 key financials · XBRL
- Revenue
- $90M
- +15.1% YoY
- Net income
- −$17M
- −226.3% YoY
- Operating margin
- -1.8%
- EPS (diluted)
- −$0.05
- −225.0% YoY
Source: XBRL data from the MANNKIND CORP (MNKD) Q1 2026 10-Q on SEC EDGAR. USD.
MANNKIND CORP Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $90.2M, up 15% YoY from $78.4M, led by commercial product sales up 79% to $33.9M
- Commercial product gross margin 78% vs 80% YoY; gross profit $26.4M vs $15.2M
- Best product: Furoscix net revenue $15.5M; weakest: V-Go net revenue down 23% YoY
- Operating cash use $5.4M vs $6.4M YoY; investing cash provided $18.7M, financing cash used $35.4M
- Liquidity $133.9M; Furoscix ReadyFlow FDA target July 26, 2026, with tariff costs a potential headwind
Risk Factors
- New trade-policy risk triggered by U.S.-China tensions and pharmaceutical tariffs, increasing costs and potentially delaying clinical development
- Tyvaso DPI concentration risk from United Therapeutics prioritizing Tresmi or ralinepag, potentially reducing royalties and collaboration revenue
- Regulatory compliance risk from FDA inspections, where major observations could require onerous corrective actions and suspend production
- V-Go operational risk from Chinese contract manufacturing, despite July 2025 duty-free treatment under HTSUS subheading 9817.00.96
- Acquisition-related financial risk from scPharma debt-funded purchase, increasing interest expense, leverage, and debt-service requirements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MANNKIND CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.